A5059167788- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Immune Cell Function and Interaction
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- Immune cells in cancer
- Renal and related cancers
- Cell Adhesion Molecules Research
- RNA Research and Splicing
- Single-cell and spatial transcriptomics
- HER2/EGFR in Cancer Research
- Molecular Biology Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Neuroblastoma Research and Treatments
- Renal cell carcinoma treatment
- Cancer-related Molecular Pathways
- Testicular diseases and treatments
- Sarcoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cell Image Analysis Techniques
- Peptidase Inhibition and Analysis
University Medical Center Hamburg-Eppendorf
2016-2025
Universität Hamburg
2016-2025
University of North Carolina at Chapel Hill
2022
University of Nebraska Medical Center
2022
VA Western New York Healthcare System
2022
Taipei Institute of Pathology
2021
Pathologie Hamburg-West
2020
Martini-Klinik
2017-2020
Kaiser-Franz-Josef-Spital
2013-2016
Abstract Background The clinical course of prostate cancer (PCa) is highly variable, demanding an individualized approach to therapy. Overtreatment indolent PCa cases, which likely do not progress aggressive stages, may be associated with severe side effects and considerable costs. These could avoided by utilizing robust prognostic markers guide treatment decisions. Results We present a random forest-based classification model predict behaviour cancer. DNA methylation changes between cases...
Abstract Background Tumor protein 63 (p63) is a transcription factor of the p53 gene family involved in differentiation several tissues including squamous epithelium. p63 immunohistochemistry broadly used for tumor classification but published data on its expression cancer conflicting. Methods To comprehensively catalogue expression, tissue microarrays (TMAs) containing 12,620 samples from 115 entities and 76 normal types were analyzed. Results was seen various epithelium urothelium. At...
Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment triple negative breast cancer and urothelial carcinoma.A tissue microarray containing 18,563 samples from 150 different tumor types subtypes as well 608 76 normal was analyzed by TROP2 immunohistochemistry.TROP2 positivity found in 109 categories, including squamous carcinomas various origins, urothelial, breast, prostate, pancreatic, ovarian cancers (>95%...
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand impact BGN on prognosis and its relationship to molecularly defined subsets, we analyzed expression by immunohistochemistry tissue microarray containing 12,427 cancers. Seventy-eight percent 11,050 interpretable cancers showed expression, which was considered as low intensity 47.7% high 31.1% protein rose with increasing pathological tumor stage,...
TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel therapies. Here, we analysed two different types of tissue microarrays healthy lymphatic various inflamed tissues, colorectal lung cancers, as well >1700 tumour samples from 86 entities and/or PD-1 by bright field multiplex fluorescence immunohistochemistry. was detected in CD8 + cytotoxic T cells, CD4 helper FOXP3 regulatory NK but not CD11c dendritic CD68 macrophages, CD20 B lymphocytes. expression...
Abstract Background Cytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic type I group and primarily expressed in single-layered or “simple” epithelial tissues carcinomas different origin. Methods To systematically determine CK18 expression normal cancerous tissues, 11,952 tumor samples from 115 types subtypes (including carcinomas, mesenchymal biphasic tumors) as well 608 76 tissue were analyzed by immunohistochemistry a microarray format. Results was cells...
Abstract Background The E-Cadherin gene ( CDH1, Cadherin 1 ), located at 16q22.1 encodes for a calcium-dependent membranous glycoprotein with an important role in cellular adhesion and polarity maintenance. Methods To systematically determine protein expression normal cancerous tissues, 14,637 tumor samples from 112 different types subtypes as well 608 of 76 tissue were analyzed by immunohistochemistry microarray format. Results was strongly expressed epithelial cells most organs. From 77...
Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune activity and has gained interest in the era checkpoint therapy.To understand T cell dynamics tumor microenvironment, we used multiplex fluorescence immunohistochemistry to quantitate proliferation (Ki67 co-expression) tissue microarrays from 1107 colorectal, 642 renal cell, 1066 breast, 375 ovarian, 451 pancreatic 347 gastric cancer samples.The density percentage proliferating (Ki67+) cells were both highly...
Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. immunostaining used as diagnostic marker for breast and urothelial cancer but can also occur other neoplasms. Methods: To evaluate normal tumor tissues, tissue microarray containing 16,557 samples from 131 different types subtypes 608 of 76 was analyzed by immunohistochemistry. Results: positivity found 69 including 23 (18%) with at least one strongly positive tumor. Highest rates occurred noninvasive...
Cadherin-17 (CDH17) is a membranous cell adhesion protein predominantly expressed in intestinal epithelial cells. CDH17 therefore considered possible diagnostic and therapeutic target. This study was to comprehensively determine the expression of cancer further assess utility immunohistochemistry (IHC). A tissue microarray containing 14,948 interpretable samples from 150 different tumor types subtypes as well 76 normal analyzed by IHC. In tissues, staining seen epithelium intestine...
Trichorhinophalangeal syndrome 1 (TRPS1) is a nuclear protein highly expressed in breast epithelial cells. TRPS1 immunohistochemistry (IHC) has been suggested as cancer marker. To determine the diagnostic and prognostic utility of IHC, tissue microarrays containing 19,201 samples from 152 different tumor types subtypes were analyzed. GATA3 IHC was performed previous study. staining seen 86 categories with 36 at least one strongly positive case. predominated various carcinomas (51%-100%),...
Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It of interest because possible prognostic role differential expression tumors its as target for indatuximab, monoclonal antibody coupled with cytotoxic agent. To comprehensively analyze CD138 neoplastic tissues, we used tissue microarrays (TMAs) analyzing immunohistochemically detectable 2,518 samples from 85 different tumor entities 76 types. The data showed that abundant...
Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression 2,197 breast cancers. LPCAT1 staining was found 97.8% 1,774 interpretable tumors, including 48.1% weak, 28.7% moderate, and 14.4% strong expression. The frequency positivity depended on the histological tumor type. Moderate or more cancers no special type (NST) (46.2%) than lobular...
Abstract Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand role deletion cancer we took advantage our large tissue microarray comprising more than 12 000 samples with full pathological and clinical follow‐up data. Fluorescence situ hybridization probes for ENOX1 (13q14.11) retinoblastoma gene ( RB1 , 13q14.2) was employed. A found 21% 7375 analyzable cancers. were always heterozygous associated high Gleason grade P <...
Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitory immune checkpoint receptor putative target novel immunotherapies. To study patterns TIGIT expression in surrounding malignant including Hodgkin cells, Reed-Sternberg histiocytic microenvironment (ME) tissue microarray (TMA) was constructed from punches measuring 2 mm diameter obtained...
p16 (CDKN2A) is a member of the INK4 class cell cycle inhibitors, which often dysregulated in cancer. However, prevalence expression different cancer types controversial. 15,783 samples from 124 tumor and 76 normal tissue were analyzed by immunohistochemistry microarray format. was detectable 5,292 (45.0%) 11,759 interpretable tumors. Except adenohypophysis islets Langerhans, staining largely absent tissues. In cancer, highest positivity rates observed uterine cervix squamous carcinomas...
Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number tumor types, but unanimous picture on PD-L1 expression across cancer types lacking.We analyzed immunohistochemical 11,838 samples from 118 human and its relationship with infiltrating CD8 positive lymphocytes.At cut-off level 10% cells, positivity was seen 85 (72%) including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%),...
Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response taxane-based therapies in several cancer types, but its relevance prostate is unknown.In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 cancers.MAPT absent normal epithelial cells detectable 1004 (8.2%) of 12,313 interpretable cancers. Its associated with advanced tumor stage, high Gleason grade, positive lymph nodes,...
ESRPs are master splice regulators implicated in alternative mRNA splicing programs important for epithelial-mesenchymal transition (EMT) and tumor progression. ESRP1 was identified some tumors as good or worse predictor of outcome, but colorectal cancer (CRC) the prognostic value relation with mesenchymal variants is not clear. Here, we studied 68 CRC cases, compared tissue expression clinical data EMT gene patterns conditional cells deficient expression.Around 72% patients showed global...
Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that quantity tumor infiltrating lymphocytes (TILs) influences likelihood response to immune inhibitors. Here, we set out assess density CD8+ wide range different types and subtypes.The was compared across using tissue microarrays (TMAs) composed up 50 samples each from 84 subtypes. In total 2652 cancers 608 normal tissues were...
Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents potential obstacle the analysis of predicitive biomarkers. MSI been reported in pancreatic cancer, but data on possible extent intratumoral are lacking.To study tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6.In six suspicious cases, large...
Loss of the Y-chromosome is a common event in different tumor types but its prevalence and clinical relevance renal cell tumors still not understood.It was aim this study to estimate frequency Y-loss kidney neoplasms. A cohort 1,252 male analyzed tissue microarray format by fluorescence in-situ hybridization (FISH).Y-loss found 47% tumors. The alteration varied markedly between subtypes. most prevalent papillary carcinoma (RCC) (77%) followed chromophobe RCC (60%), oncocytoma (51%), clear...